key: cord-0043730-lb0ymhue
authors: Pragathi, Yazala Jyothsna; Sreenivasulu, Reddymasu; Veronica, Deekala; Raju, Rudraraju Ramesh
title: Design, Synthesis, and Biological Evaluation of 1,2,4-Thiadiazole-1,2,4-Triazole Derivatives Bearing Amide Functionality as Anticancer Agents
date: 2020-05-22
journal: Arab J Sci Eng
DOI: 10.1007/s13369-020-04626-z
sha: 5afcb93b060494aee5f437a093263d0888520d4b
doc_id: 43730
cord_uid: lb0ymhue

A novel library of amide functionality having 1,2,4-thiadiazole-1,2,4-triazole (8a–j) analogs was designed, synthesized, and structures were characterized by (1)H NMR, (13)C NMR, and mass (ESI–MS) spectral data. Further, all compounds were evaluated for their anticancer activities against four different cancer cell lines including breast cancer (MCF-7, MDA MB-231), lung cancer (A549), and prostate cancer (DU-145) by MTT reduction assay method, and etoposide acts as a standard drug. The results confirmed that majority of the synthesized compounds showed moderate to potent anticancer activities aligned with four cell lines. Among the synthesized compounds, 8b, 8c, 8d, 8e, 8g and 8i displayed more potent activity along with inhibitory concentration values ranging from 0.10 ± 0.084 to 11.5 ± 6.49 µM than the standard IC(50) values, which ranges from 1.91 ± 0.84 to 3.08 ± 0.135 µM, respectively. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s13369-020-04626-z) contains supplementary material, which is available to authorized users.

Cancer is very dangerous disease with uncontrolled growth and rapid spreading of abnormal cells [1] . Several external and internal factors are caused to abnormal growth of cell lines and induced the different cancers [2] [3] [4] [5] [6] [7] . Currently, three types of treatment are available for cancer disease including chemotherapy, radiotherapy, and surgery [8] . The standard treatment for cancer patients is chemotherapy, in which different chemotherapeutic agents are used to kill the cancer cells without any harmful effective on normal kidney cells [9] [10] [11] [12] [13] .

Nitrogen atoms contain heterocyclic ring moieties that are present both in natural products and in synthetic derivatives and exhibited potent anticancer activities against different human cancer cell lines [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] . Three nitrogen atoms containing heterocyclic ring such as 1,2,4-triazoles play an important critical role in the structural elucidation of various natural products [33] and are able to form hydrogen bonding with suitable targets leading to improving of pharmacokinetics, pharmacological, and toxicological properties [34, 35] . These 1,2,4-triazole derivatives are associated with different pharmaceutical activities such as anticancer [36] , antibacterial [37] , antitubercular [38] , antifungal [39] , antiviral [40] , analgesic [41] , anti-inflammatory [42] , and tubulin inhibitors [43] . Letrozole (1, Fig. 1 ) [44, 45] is a triazole structural unit containing aromatase inhibitor and is used for cancer treatment.

Similarly, 1,2,4-thiadiazoles are considered as most significant subclass of bioactive five-membered organic compounds for medicinal chemistry [46] and showed a remarkable biological activities such as cyclooxygenase inhibitors [47] , human leukemia [48] , antibacterial [49] , antiulcerative [50] , antihypertensive [51] , cathepsin B inhibitors [52] , anticonvulsant [53] , antidiabetic [54] , anti-inflammatory [47] , and allosteric modulators [55] . One of the anticancer drug scaffolds like 3,5-bis(pyridin-3-yl)-1,2,4-thiadiazole (2) is inhibitor of aromatase and used for treatment of various types of cancers [56, 57] . Structures of letrozole (1) and 3,5-bis(pyridine-3-yl)-1,2,4thiadiazole (2) Previously, we reported the synthesis of a library of novel 2-(4-arylsubstituted-1H-1,2,3-triazol-1-yl)-N-{4-[2-(thiazol-2-yl)benzo[d]thiazol-6-yl]phenyl}acetamide derivatives and screened their anticancer activities against MCF-7, A549, Colo-205, and A2780 cell lines with etoposide as standard drug. The anticancer target compounds reported by us and the literature reveal hazardous solvent usage, harsh reaction conditions, and longer reaction sequences. To overcome the above drawbacks and inspired by special features of both 1,2,4-triazole and 1,2,4-oxadiaxole, we have to design and synthesize new amide functionality bearing 1,2,4-thiadiazole-1,2,4-triazole derivatives (8a-j). These derivatives were examined for their anticancer activities against four different human cancer cell lines like breast cancer (MCF-7, MDA MB-231), lung cancer (A549), and prostate cancer (DU-145). These derivatives may act as drug lead molecules in cancer chemotherapy.

All the solvents, salts, reagents, and fine chemicals were purchased from Sigma-Aldrich and Alfa Aesar companies. These chemical items were used without further purification. 1 H and 13 C NMR spectra were recorded with 400 MHz and 300 MHz frequency Gemini Varian-VXR-unity instruments. Chemical shifts (δ) were noted in ppm toward downfield with respect to tetramethylsilane as internal standard. ESI spectra were recorded at 3.98 kV capillary voltages with micro-mass, Quattro LC instrument using ESI + software. Melting points were noted with the help of electrothermal melting point apparatus. 

A mixture of 5-(3,4,5-trimethoxyphenyl)-3-p-tolyl-1H-1,2,4-triazole (5) (12 g, 0.037 mol), 3,4,5-trimethoxy benzamidine ( The compound 5-(3,4,5-trimethoxyphenyl)-3-(4-(3-(3,4,5trimethoxyphenyl)-1,2,4-thiadiazol-5-yl)phenyl)-1H-1,2,4triazole (6) (500 mg, 0.891 mol) was dissolved in 40 mL of dry acetonitrile, followed by addition of benzoyl chloride (7a) (0.1 mL, 0.891 mmol) and Cs 2 CO 3 (580 mg, 1.78 mol). The reaction mixture allowed for stirring at room temperature over a time period of 12 h. After completion of reaction, the reaction mass was washed with 3 mL water and diluted with dichloromethane (3 × 3 9 mL). It was dried on anhydrous Na 2 SO 4 . The crude residue was purified with silica gel through column chromatography by using 1:1 ratio ethyl acetate/hexane solvent mixture and then afforded pure yellow color compound 8a in 310. 8 

This compound 8b was synthesized by the same method involved in the synthesis of 8a, employing 6 (500 mg, 0.891 mol) with 3,4,5-trimethoxybenzoyl chloride (7b) (206 mg, 0.891 mmol), Cs 2 CO 3 (580 mg, 1.78 mol), and the crude residue was purified with silica gel through column chromatography by 

This compound 8d was prepared following the method described for the preparation of the compound 8a, employing 6 (500 mg, 0.891 mol) with 4-methoxybenzoyl chloride (7d) (0.12 mL, 0.891 mol), Cs 2 CO 3 (580 mg, 1.78 mol), and the crude residue was purified with silica gel through column chromatography by 

This compound 8e was synthesized by the same method involved in the synthesis of 8a, employing 6 (500 mg, 0.891 mol) with 4-nitrobenzoyl chloride (7e) (165 mg, 0.891 mol), Cs 2 CO 3 (580 mg, 1.78 mol), and the crude residue was purified with silica gel through column chromatography by 

This compound 8f was synthesized by the same method involved in the synthesis of 8a, employing 6 (500 mg, 0.891 mol) with 3,5-dinitrobenzoyl chloride (7f) (205 mg, 0.891 mol), Cs 2 CO 3 (580 mg, 1.78 mol), and the crude residue was purified with silica gel through column chromatography by 

This compound 8g was synthesized by the same method involved in the synthesis of 8a, employing 6 (500 mg, 0.891 mol) with 4-chlorobenzoyl chloride (7 g) (0.11 mL, 0.891 mol), Cs 2 CO 3 (580 mg, 1.78 mol), and the crude residue was purified with silica gel through column chromatography by 

This compound 8h was synthesized by the same method involved in the synthesis of 8a, employing 6 (500 mg, 0. 

This compound 8i was synthesized by the same method involved in the synthesis of 8a, employing 6 (500 mg, 0.891 mol) with 4-cyanobenzoyl chloride (7i) (148 mg, 0.891 mol), Cs 2 CO 3 (580 mg, 1.78 mol), and the crude residue was purified with silica gel through column chromatography by 

This compound 8j was synthesized by the same method involved in the synthesis of 8a, employing 6 (500 mg, 0.891 mol) with 4-methylbenzoyl chloride (7j) (0.8 mL, 0.891 mmol), Cs 2 CO 3 (580 mg, 1.78 mmol), and the crude residue was purified with silica gel through column chromatography by 

Individual wells microtiter plate from a 96-well tissue culture was inoculated with 100 μL of complete medium containing 1 × 10 4 cells. These microtiter plates were incubated at a temperature of 37°C in 5% CO 2 -humidified incubator over a time period of 18 h prior to the experiment. After the removal of medium, a fresh medium of 100 μL containing both the test compounds and standard drug and etoposide at a variable concentrations of 0.5, 1, 2, and 4 μM was added to each well and incubated over 24-h time period at 37°C temperature. Now, this medium was removed and replaced by 10 μL MTT assay dye. Again, the plates were allowed for incubation at a temperature of 37°C over 2-h time period. The obtained formazan crystals were dissolved in 100 μL extraction buffer. The OD value was read with multimode Varioskan Instrument, Themo Scientific microplate reader at 570 nm. The % of DMSO-d 6 in the medium should not exceed 0.25% at any time. Each of the data of the IC 50 values were represented as mean of ± SD values that means each experiment was performed three times.

The synthesis of 1,2,4-thiadiazole-1,2,4-triazole derivatives bearing amide functionality (8a-j) is shown in Scheme 1. Starting material 3,4,5-trimethoxybenzamidine (3) 

The new library of 1,2,4-thiadiazole-1,2,4-triazole derivatives having amide functionality (8a-j), was examined for their anticancer activity toward a pane of four different human cancer cell lines such as breast cancer (MCF-7, MDA MB-231), lung cancer (A549), and prostate cancer (DU-145) by MTT assay and compared with the standard reference etoposide. The obtained results were presented as IC 50 (μM) values in Table 1 . The results indicated that most of the synthesized compounds exhibited moderate to excellent anticancer activity aligned with four cell lines. Among the library of examined compounds, compounds 8b, 8c, 8d, 8e, 8g, and 8i displayed more potent activity with IC 50 values ranging from 0.10 ± 0.084 to 11.5 ± 6.49 μM and standard showed IC 50 value range as 1.91 ± 0.84 μM to 3.08 ± 0.135 μM. Further, all these compounds were investigated for structure-activity relationship (SARs) studies. Compound 8b with electron-donating group (3,4,5- CuBr, Cs 2 CO 3 1.08 μM) . When 3,5-dinitro group was introduced, 4-bromo substituents on the phenyl ring resulted compounds, namely 8f and 8h, were displayed very poor activity on all cell lines. Interestingly, compound 8i with 4-cyano electron-withdrawing group showed better anticancer activity (MCF-7 1.27 ± 0.92 μM; A549 1.90 ± 0.46 μM; DU145 0.60 ± 0.014 μM, MDA MB-231 1.59 ± 0.37 μM) than 8g. Compound 8j with weak electron-donating group on the phenyl ring demonstrated moderate activity.

From the structure-activity relationship studies, it can be concluded that the presence of three electron-donating -OCH 3 group at 3,4,5 positions on phenyl ring displayed excellent potent anticancer activities against four specified cancer cell lines. The decrease in anticancer activity would be observed with two -OCH 3 groups at 3,5 positions and one -OCH 3 group at 4th position. The presence of strongwithdrawing group -NO 2 at 3, 5 positions on phenyl ring displayed very less anticancer activity against specified cancer cell lines, when compared to one -NO 2 group at 4th position. In this series, cytotoxicity effect decreases from the electron-donating group to electron-withdrawing group derivatives.

The new library of 1,2,4-thiadiazole-1,2,4-triazole derivatives having amide functionality (8a-j) was designed, synthesized, and examined for their anticancer activities against four different human cancer cell lines including breast cancer (MCF-7, MDA MB-231), lung cancer (A549), and prostate cancer (DU-145) by making use of MTT assay. Here, Etoposide acts as standard drug, and the obtained results were presented as IC 50 (μM) values. The results indicated that most of the synthesized compounds exhibited moderate to excellent anticancer activity aligned with four cell lines. Among them, compounds 8b, 8c, 8d, 8e, 8g, and 8i displayed more potent activity with IC 50 values ranging from 0.10 ± 0.084 to 11.5 ± 6.49 μM and standard showed IC 50 value ranges from 1.91 ± 0.84 μM to 3.08± 0.135 μM. These derivatives may act as drug lead molecules in cancer chemotherapy.

Global cancer statistics

Lung cancer risk and cigarette smoking, lung tuberculosis according to histologic type and gender in a population based case-control study

NF-kappa B functions in synaptic signalling and behaviour

Free radicals in chemical carcinogenesis

Cancer-related inflammation

Growth hormone, the insulin-like growth factor axis, insulin and cancer risk

Mechanisms linking pathogensassociated inflammation and cancer

Cancer treatment-objectives and quality of life issues. Malays

Novel antineoplastic agents

Analysis of anticancer drugs: a review

Molecular aspects of cancer cell resistance to chemotherapy

Cancer drug resistance: an evolving paradigm

In vitro and in vivo models for analysis of resistance to anticancer molecular molecular therapies

Synthesis and biological evaluation of benzoxazole fused combretastatin derivatives as anticancer agents

Synthesis and biological evaluation of benzimidazole fused ellipticine derivatives as anticancer agents

Synthesis, cytotoxic activity and docking studies of new 4-aza podophyllotoxin derivatives

Synthesis, antiproliferative and apoptosis induction potential activities of novel bis(indolyl)hydrazide-hydrazone derivatives

MdH: Design and synthesis of new 2,5-disubstituted 1,3,4-oxadiazole analogues as anticancer agents

Novel 1,3,4-oxadiazole fused thiadiazole derivatives: synthesis and study of anticancer activities

Synthesis and biological evaluation of oxadiazole incorporated ellipticine derivatives as anticancer agents

Synthesis, anticancer evaluation and molecular docking studies of bis(indolyl)triazinones, nortopsentin analogues

Synthesis, biological evaluation and docking studies of 1,3,4-oxadiazole fused benzothiazole derivatives for anticancer drugs

Synthesis, antiproliferative activity and molecular docking studies of curcumin analogues bearing pyrazole ring

Synthesis of chalcone incorporated quinazoline derivatives as anticancer agents

Synthesis and biological evaluation of 1,3,4-oxadiazole linked bis indole derivatives as anticancer agents

Synthesis and anticancer evaluation of indazole-aryl hydrazide-hydrazone derivatives

Design, synthesis and anticancer evaluation of carbazole fused aminopyrimidine derivatives

Synthesis, biological evaluation and molecular docking studies of pyridine incorporated chalcone derivatives as anticancer agents

Synthesis, antitumor evaluation and molecular docking studies of indole-indazolyl hydrazide-hydrazone derivatives

Synthesis and biological evaluation of 1,2,4-oxadiazole linked imidazopyrazine derivatives as anticancer agents

Design, synthesis and anticancer evaluation of 1,2,3-triazole linked 1,2-isoxazole-imidazo[4,5-b]pyridine derivatives

Design, synthesis and anticancer evaluation of 1,2,4-oxadiazole functionalized quinolone derivatives

Characterization of brassinazole, a triazole-type brassinosteroid biosynthesis inhibitor

Hepatoprotective activity of Inula cappa DC. Aqueous extract against carbon tetrachloride induced hepatotoxicity in Wistar rats

Development of the 1,2,4-triazole-based anticonvulsant drug candidates acting on the voltage-gated sodium channels. Insights from in vivo, in vitro, and in silico studies

New bisaminomercapto triazoles and bis-triazolothiadiazoles as possible anticancer agents

Synthesis and antimicrobial activities of novel quinoline derivatives carrying 1,2,4-triazole moiety

Triazole derivatives and their anti-tubercular activity

Design, synthesis, biological activities and DFT calculation of novel 1,2,4-triazole Schiff base derivatives

Novel 1,2,4-triazole and imidazole derivatives of l-ascorbic and imino-ascorbic acid: synthesis, anti-HCV and antitumor activity evaluations

Studies on synthesis and pharmacological activities of 3,6-disubstituted-1,2,4-triazolo[3,4-b]-1,3,4-thiadiazoles and their dihydro analogues

4-dichlorophenoxy)methyl)-1,2,4-triazolo(thiadiazoles and thiadiazines) as anti-inflammatory and molluscicidal agents

Highly potent triazole-based tubulin polymerization inhibitors

Synthesis of casimiroin and optimization of its quinone reductase 2 and aromatase inhibitory activities

A high-throughput screen to identify inhibitors of aromatase (CYP19)

Synthesis and anticancer activity of 5-(3-indolyl)-1,3,4-thiadiazoles

Novel 1,2,4-oxadiazoles and 1,2,4-thiadiazoles as dual 5-lipoxygenase and cyclooxygenase inhibitors

and α-bromoacryloyl moieties as potent apoptosis inducers on human myeloid leukaemia cells

Structure-activity relationships of cephalosporins having a (dimethyl isoxazolidi nio) vinyl moiety at their 3-position

Thiadiazole compounds useful as inhibitors of hb/kb atpase

Synthesis and angiotensin II receptor antagonistic activities of benzimidazole derivatives bearing acidic heterocycles as novel tetrazole bioisosteres

1,2,4-thiadiazole: a novel cathepsin B inhibitor

Advances in the synthesis and recent therapeutic applications of 1,2,4-thiadiazole heterocycles

Heteroaryl benzamide derivatives for use as Glk activators in the treatment of diabetes

Synthesis and biological evaluation of 2,3,5-substituted [1,2,4]thiadiazoles as allosteric modulators of adenosine receptors

Optimizing thiadiazole analogues of resveratrol versus three chemopreventive targets

Synthesis and in vitro anticancer activity of 3,5-bis(indolyl)-1,2,4-thiadiazoles